Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 12/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610423 | 0.77 | KDM4E (0.54) | TNK2SRCKDM4EALDH1A1HPGD | |
| SCHEMBL20522349 | 0.77 | KDM4E (0.54) | TNK2SRCKDM4EALDH1A1HPGD | |
| SCHEMBL14654207 | 0.77 | BTK (0.52) | BTK | |
| SCHEMBL11146481 | 0.72 | ALDH1A1 (0.45) | TNK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1003068 | 0.71 | DYRK1A (0.53) | KDM4EALDH1A1HPGDKMT2ADYRK1A | |
| SCHEMBL9772745 | 0.71 | KDM4E (0.51) | TNK2KDM4EALDH1A1HPGD | |
| SCHEMBL18447982 | 0.71 | TDP1 (0.61) | KDM4EALDH1A1HPGDKMT2ADYRK1A | |
| SCHEMBL4357975 | 0.71 | TNK2 (1.00) | TNK2BTK | |
| SCHEMBL13325864 | 0.70 | QPCT (0.51) | KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL14525860 | 0.69 | KDM4E (0.61) | KDM4EALDH1A1HPGDKMT2ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3CA | TNK2 150/4885SRC 235/4885BTK 139/4885 |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | TNK2 136/4885SRC 216/4885BTK 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.